Brief: Pharnext Announces New Results From Ongoing Open-Label Phase III Extension Study Of PXT3003
16/05/2022 08:41
May 16 (Reuters) - PHARNEXT SA PHARN.PA :
* NEW DATA FROM ONGOING OPEN-LABEL PHASE III EXTENSION STUDY
OF
PXT3003, PLEO-CMT-FU TRIAL, SUGGEST GOOD SAFETY PROFILE AND
CONTINUOUS TREATMENT EFFECT OF PXT3003 MEASURED ON OVERALL
NEUROPATHY LIMITATION SCALE AFTER 5 YEARS OF TOTAL TRIAL TIME
* NEW DATA FROM THE OPEN-LABEL PLEO-CMT-FU TRIAL SHOWS
SUSTAINED
BENEFIT WITHPXT3003 INPATIENTS WITH CHARCOT-MARIE-TOOTH DISEASE
TYPE 1A AFTER 5 YEARS OF TOTAL TRIAL TIME
Source text for Eikon: urn:newsml:reuters.com:*:nGNE4dBcv7
Further company coverage: PHARN.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development